Australian shares closed the week higher, tracking Asian markets, despite Wall Street's concerns about high interest rates.
The S&P/ASX 200 Index rose 0.6% or 49.3 points to close at 8,250.5.
Anticipated fewer rate cuts from the US Federal Reserves, coupled with potential inflationary policies from President-elect Trump hit shares while sending bond yields higher and making the dollar stronger, Reuters reported.
In company news, the Australian Securities Exchange (ASX:ASX) is looking to clamp down on listed companies allegedly providing misleading or evasive information in their market disclosures, according to a report by The Australian.
Imugene (ASX:IMU) dosed the first Australian patient for its phase 1b clinical trial of its CAR T-cell therapy azer-cel at the Royal Prince Alfred Hospital in Sydney.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.